Recently, Hengrui Pharmaceuticals according to imitation 3 categories of reported hydrochloric acid right metomide sodium chloride injection into the administrative approval stage, is expected to be approved recently and as reviewed.
sodium chloride injection for sedatives, Milnet data show that in 2019, China's public medical institutions terminal right mitometrid sales of more than 3.5 billion yuan.
Sodium chloride injection is a relatively selective alpha2-epinephrine-subject agonist that is suitable for sedation in patients who are not intestored before or during surgery.
hydrochloride sodium chloride injection was developed by Hospira and was first approved in the United States in 2013. according to
meters of intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal right-right Meito medding sales of more than 3.5 billion yuan, 2020H1 sales of more than 1.3 billion yuan.
At present, china has Hengrui Pharmaceuticals, Yangzijiang Pharmaceutical Group, Enhua Pharmaceuticals and other 11 enterprises of hydrochloric acid right metomide injection was approved, hydrochloric acid right metomide sodium chloride injection has not been approved for the market.
4 enterprises, such as Hengrui Pharmaceuticals, Colum Pharmaceuticals, Vit Pharmaceuticals and Yangzijiang Pharmaceutical Group, submitted applications for the listing of sodium chloride injections of right metomide hydrochloride according to the imitation 3 categories.
Thirt metomide hydrochloride injection imitation application source: Mi net one-click retrieval Hengrui medicine hydrochloric acid right metomide sodium chloride injection registration status has been changed to "in approval", if successfully approved will become the first imitation of the species.
source: MiNet Database, NMPA